The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
Open accessAbstract
Background and objectives: few studies have reported the drug retention rate (DRR) of biologic drugs in juvenile idiopathic arthritis (JIA), and none of them has specifically investigated the DRR of interleukin (IL)-1 inhibitors on systemic JIA (sJIA). This study aims to describe IL-1 inhibitors DRR and evaluate predictive factors of drug survival based on data from a real-world setting concerning sJIA. Methods: Medical records from sJIA patients treated with anakinra (ANA) and canakinumab (CAN) were retrospectively analyzed from 15 Italian tertiary referral centers. Results: Seventy seven patients were enrolled for a total of 86 treatment courses. The cumulative retention rate of the IL-1 inhibitors at 12-, 24-, 48- and 60-months of follow-up was 79.9%, 59.5%, 53.5% and 53.5% respectively, without any statistically significant differences between ANA and CAN (p=0.056), and between patients treated in monotherapy compared to the subgroup co-administered with conventional immunosuppressors (p=0.058). On the contrary, significant differences were found between biologic-naive patients and those previously treated with biologic drugs (p=0.038) and when distinguishing according to adverse events (AEs) occurrence (p=0.04). In regression analysis, patients pre-treated with other biologics (HR=3.357 [C.I. 1.341-8.406], p=0.01) and those experiencing AEs (HR=2.970 [C.I. 1.186-7.435], p=0.020) were associated with a higher hazard ratio of IL-1 inhibitors withdrawal. The mean treatment delay was significantly higher among patients discontinuing IL-1 inhibitors (p=0.0002). Conclusions: Our findings suggest an excellent overall DRR for both ANA and CAN that might be further augmented by paying attention to AEs and employing these agents as first-line biologics in the early stages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Petty, R. E., Southwood, T. R. E., Manners, P. J., Baum, J., Glass, D. N., Goldenberg, J., He, X.-H., Maldonado-Cocco, J. A., Orozco-Alcalá, J., Prieur, A., et al. (2004) · PubMed · Cited by 4,176
Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Ruperto, N., Brunner, H. I., Quartier, P., Constantin, T., Wulffraat, N., Horneff, G., Brik, R., McCann, L., Kasapcopur, O., Rutkowska-Sak, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205099 · Cited by 713
Self-citationQuartier, P., Allantaz, F., Cimaz, R., Pillet, P., Messiaen, C., Bardin, C., Bossuyt, X., Boutten, A., Bienvenu, J., Duquesne, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.134254 · Cited by 558
Self-citationNigrovic, P. A., Mannion, M., Prince, F. H. M., Zeft, A., Rabinovich, C. E., van Rossum, M. A. J., Cortis, E., Pardeo, M., Miettunen, P. M., Janow, G., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30128 · Cited by 463
Self-citationMinoia, F., Davì, S., Horne, A., Demirkaya, E., Bovis, F., Li, C., Lehmberg, K., Weitzman, S., Insalaco, A., Wouters, C., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38802 · Cited by 429
Self-citationLequerré, T., Quartier, P., Rosellini, D., Alaoui, F., De Bandt, M., Mejjad, O., Kone-Paut, I., Michel, M., Dernis, E., Khellaf, M., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.076034 · Cited by 406
Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions
Mellins, E. D., Macaubas, C., & Grom, A. A. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.68 · Cited by 330
Ringold, S., Weiss, P. F., Beukelman, T., DeWitt, E. M., Ilowite, N. T., Kimura, Y., Laxer, R. M., Lovell, D. J., Nigrovic, P. A., Robinson, A. B., et al. (2013) · Arthritis Care & Research · doi:10.1002/acr.22087 · Cited by 306
Vastert, S. J., de Jager, W., Noordman, B. J., Holzinger, D., Kuis, W., Prakken, B. J., & Wulffraat, N. M. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38296 · Cited by 258
Review: Is There a Window of Opportunity for Treatment of Systemic Juvenile Idiopathic Arthritis?
Nigrovic, P. A. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38615 · Cited by 217
Research works printed but not linked: 3
- Davies, 2017, Mortality rates are increased in patients with systemic juvenile idiopathic arthritis., Arch. Dis. Child., 102, 206, 10.1136/archdischild-2016-311571 · doi:10.1136/archdischild-2016-311571
- Dewoolkar, 2017, Course, outcome and complications in children with systemic onset juvenile idiopathic arthritis., Indian J. Pediatr., 84, 294, 10.1007/s12098-017-2293-5 · doi:10.1007/s12098-017-2293-5
- Tynjälä, 2009, Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis., Ann. Rheum. Dis., 68, 552, 10.1136/ard.2007.087130 · doi:10.1136/ard.2007.087130
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions
Mohammad, S., & Thiemermann, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594150 · Cited by 585
Potent candidates for Targeted Auger Therapy: Production and radiochemical considerations
Filosofov, D., Kurakina, E., & Radchenko, V. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.12.001 · Cited by 341
Salehi, B., Sharifi-Rad, J., Cappellini, F., Reiner, Ž., Zorzan, D., Imran, M., Sener, B., Kilic, M., El-Shazly, M., Fahmy, N. M., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01300 · Cited by 293
Reviewing the Potential of Psychedelics for the Treatment of PTSD
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa018 · Cited by 260
Metadata
- Authors
- Sota, J., Insalaco, A., Cimaz, R., Alessio, M., Cattalini, M., Gallizzi, R., Maggio, M. C., Lopalco, G., La Torre, F., Fabiani, C., Pardeo, M., Olivieri, A. N., Sfriso, P., Salvarani, C., Gaggiano, C., Grosso, S., Bracaglia, C., De Benedetti, F., Rigante, D., & Cantarini, L.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2019-01-08
- Volume
- 9
- Pages
- 1526-1526
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2909739147
- Cited by
- 616
- References
- 25
- FWCI
- 90.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis. https://app.cochat.ai/papers/10.3389/fphar.2018.01526
- The paper
- Sota, J., Insalaco, A., Cimaz, R., Alessio, M., Cattalini, M., Gallizzi, R., Maggio, M. C., Lopalco, G., La Torre, F., Fabiani, C., Pardeo, M., Olivieri, A. N., Sfriso, P., Salvarani, C., Gaggiano, C., Grosso, S., Bracaglia, C., De Benedetti, F., Rigante, D., & Cantarini, L. (2019). Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2018.01526
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
